~alfa-diagnostics
Are patients with liver disease at increased risk for severe COVID-19?
What are the current data from China, Italy, and Spain regarding COVID-19?
What should be done if liver tests are stable/improving?
Where can I find information on drug interactions with experimental COVID-19 therapies?
What are the recommendations for outpatient visits during the COVID-19 pandemic?
What should be done with new clinical trials at this time?
What is the illness caused by the SARS-CoV-2 virus?
What should sponsors, investigators, and IRBs document?
What are the diagnostic methods for SARS-CoV-2 detection?
What are the potential consequences if the spread of SARS-CoV-2 is not contained quickly?
What is the SARS-CoV-2 infection rate among healthcare workers?
What factors should be considered when determining whether or not to proceed with a liver transplant?
What should research staff do if they cannot work remotely?
What should be considered in terms of dosage adjustments for immunosuppressive drugs in immunosuppressed liver disease patients with COVID-19?
What is the publication date of the clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic?
